Comparative Pharmacology
Head-to-head clinical analysis: LOTRIMIN AF versus LOTRIMIN ULTRA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOTRIMIN AF versus LOTRIMIN ULTRA.
LOTRIMIN AF vs LOTRIMIN ULTRA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits fungal cytochrome P450 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Butenafine hydrochloride is a synthetic antifungal agent that inhibits the enzyme squalene epoxidase, thereby blocking the biosynthesis of ergosterol, an essential component of fungal cell membranes, leading to fungal cell death.
Topical: Apply twice daily (morning and evening) to affected area for 2-4 weeks. Intravaginal: One 200 mg suppository vaginally at bedtime for 3 days, or one 500 mg vaginal tablet as a single dose.
Adults: Apply butenafine hydrochloride 1% cream topically once daily for 7 days for tinea pedis; for tinea cruris and tinea corporis, apply once daily for 14 days.
None Documented
None Documented
Terminal elimination half-life of absorbed clotrimazole is approximately 3.5–4 hours, but this is clinically irrelevant due to negligible systemic absorption after topical application.
Terminal elimination half-life is approximately 24-48 hours (range 20-50 hours), supporting once-daily topical application.
Less than 1% of topical clotrimazole is absorbed; absorbed drug is metabolized in the liver to inactive metabolites and excreted primarily in feces (approximately 69%) and urine (approximately 21%) via biliary and renal routes.
Primarily fecal (approx. 80%) as unchanged drug and metabolites; renal excretion accounts for <10% of the dose.
Category C
Category C
Topical Antifungal
Topical Antifungal